Regenxbio (RGNX) Gains from Sales and Divestitures (2019 - 2025)
Regenxbio (RGNX) recorded quarterly Gains from Sales and Divestitures of $743000.0 in Q4 2025, up 1.5% quarter-over-quarter from $732000.0 in Q3 2025, and up 88.1% on a YoY basis from $395000.0 in Q4 2024.
Regenxbio (RGNX) Gains from Sales and Divestitures (2019 - 2025) Analysis & Trends
Regenxbio's Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $743000.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures rose 88.1% year-over-year to $743000.0; the TTM figure through Dec 2025 stood at $743000.0 (up 88.1% YoY), while the FY2025 annual figure was $743000.0, up 88.1% from the prior year.
- Gains from Sales and Divestitures was $743000.0 for Q4 2025 at Regenxbio, up from $732000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $743000.0 in Q4 2025 to a low of $68.0 in Q4 2022.
- Historically, Gains from Sales and Divestitures has averaged $306191.8 across 4 years, with a median of $252000.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Gains from Sales and Divestitures soared 269017.65% in 2023, then soared 67.04% in 2025.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $68.0 in 2022, then jumped by 269017.65% to $183000.0 in 2023, then surged by 115.85% to $395000.0 in 2024, then jumped by 88.1% to $743000.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $743000.0 (Q4 2025), $732000.0 (Q3 2025), and $598000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Regenxbio | 315.63 Mn | 85.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 743,000.00 |
| Dec 31, 2025 | 743,000.00 |
| Sep 30, 2025 | 732,000.00 |
| Sep 30, 2025 | 732,000.00 |
| Jun 30, 2025 | 598,000.00 |
| Jun 30, 2025 | 598,000.00 |
| Mar 31, 2025 | 546,000.00 |
| Mar 31, 2025 | 546,000.00 |
| Dec 31, 2024 | 395,000.00 |
| Dec 31, 2024 | 395,000.00 |
| Sep 30, 2024 | 390,000.00 |
| Sep 30, 2024 | 390,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Mar 31, 2024 | 321,000.00 |
| Mar 31, 2024 | 321,000.00 |
| Dec 31, 2023 | 183,000.00 |
| Dec 31, 2023 | 183,000.00 |
| Sep 30, 2023 | 179,000.00 |
| Sep 30, 2023 | 179,000.00 |